RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
RXIIW was delisted on the 16th of November, 2018.
4 hedge funds and large institutions have $1.16M invested in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
11% less capital invested
Capital invested by funds: $1.31M → $1.16M (-$149K)
20% less funds holding
Funds holding: 5 → 4 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$238K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$5.62K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $492K | -$5.62K | -31,796 | -1% |
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $489K | – | – | – |
|
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| $172K | -$238K | -1,346,344 | -63% |
|
|
LTFS
4
Ladenburg Thalmann Financial Services
Miami,
Florida
| $7K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$1K | -5,600 | Closed |
|
RXIIW Hedge Fund Activity: Q1 2017 in Review
4 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) for Q1 2017, worth a combined $1.16M — down 11% from $1.31M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RXIIW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Hudson Bay Capital Management, cutting an estimated $238K.
- 4 institutional investors held RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 (RXIIW) as of Q1 2017, down from 5 in Q4 2016.
- Funds reported $1.16M of RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 stock for Q1 2017, down 11% quarter-over-quarter.
- 0 funds opened new RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 positions in Q1 2017 and 1 closed out, a net change of -1 holder.
- The largest RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021 seller in Q1 2017 was Hudson Bay Capital Management, an estimated $238K sold.
Based on aggregated 13F filings for Q1 2017.